Researchers developed and validated a sequencing method for mRNA vaccines, moving the manufacturing field forward by linking established technologies with translational applications.
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?